Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Chinese data propel InflaRx anti-complement mAb into clinic for severe COVID-19 pneumonia

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

Sandi Wong, Assistant Editor
April 1, 2020 11:29 PM UTC
Updated on Apr 1, 2020 at 11:56 PM UTC

Backed by preclinical and clinical data that support blocking complement to mitigate coronavirus-mediated respiratory distress, InflaRx has begun a clinical study of its own complement inhibitor to treat COVID-19 patients with severe pneumonia.

InflaRx N.V. (NASDAQ:IFRX) announced after market close Tuesday that it has dosed the first patient in a randomized clinical trial of IFX-1, a mAb against C5a, to treat severe pneumonia due to SARS-CoV-2 infection...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Inflarx N.V.

BCIQ Target Profiles

Complement 5a (C5a)